ZBIO
$29.51
+$0.31 (1.06%)+1.06%
After HoursLoading chart...
IndexN/A
Market Cap1.86B
Enterprise Value1.59B
Income$-0.03B
Sales$0.01B
EmployeesN/A
P/E-5.87
P/S162.41
P/B6.71
P/C-9.42
EV/EBITDA-4.30
EV/SalesN/A
EPS (ttm)-5.03
EarningsN/A
Gross Margin100.00%
Oper. Margin-2113.85%
Profit Margin-3777.37%
Volume0.63M
Shs Outstand0.06B
Change1.06%
Dividend Est.N/A
Dividend Ex-DateN/A
Perf YTDN/A
Perf YearN/A
Perf 3YN/A
Perf 5YN/A
Perf 10YN/A
IPON/A
| Metric | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|
| Revenue | $5.00M | $50.00M | $0.00 |
| Cost of Revenue | $139.14M | $0.00 | $61.69M |
| Gross Profit | $-134.14M | $50.00M | $-61.69M |
| Gross Margin | -2682.78% | 100.00% | N/A |
| Operating Expenses | $29.75M | $87.15M | $14.51M |
| Operating Income | $-163.89M | $-37.15M | $-76.20M |
| Operating Margin | -3277.76% | -74.29% | N/A |
| Net Income | $-156.99M | $-37.12M | $-119.28M |
| Net Margin | -3139.76% | -74.25% | N/A |
| EPS (Basic) | $-3.76 | $-0.97 | $-3.11 |
| EBITDA | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A |
| Metric | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|
| Cash & Short Term Investments | N/A | N/A | N/A |
| Short Term Receivables | N/A | N/A | N/A |
| Inventories | N/A | N/A | N/A |
| Other Current Assets | N/A | N/A | N/A |
| Total Current Assets | N/A | N/A | N/A |
| Net Property, Plant & Equipment | N/A | N/A | N/A |
| Total Investments and Advances | N/A | N/A | N/A |
| Long-Term Note Receivable | N/A | N/A | N/A |
| Intangible Assets | N/A | N/A | N/A |
| Deferred Tax Assets | N/A | N/A | N/A |
| Other Assets | N/A | N/A | N/A |
| Total Assets | $369.97M | $68.18M | $74.58M |
| Short Term Debt Incl. Current Port. of LT Debt | N/A | N/A | N/A |
| Accounts Payable | N/A | N/A | N/A |
| Income Tax Payable | N/A | N/A | N/A |
| Other Current Liabilities | N/A | N/A | N/A |
| Total Current Liabilities | N/A | N/A | N/A |
| Long Term Debt | N/A | N/A | N/A |
| Provision for Risks Charges | N/A | N/A | N/A |
| Deferred Tax Liabilities | N/A | N/A | N/A |
| Other Liabilities | N/A | N/A | N/A |
| Total Liabilities | $57.51M | $293.90M | $266.87M |
| Non-Equity Reserves | N/A | N/A | N/A |
| Preferred Stock - Carrying Value | N/A | N/A | N/A |
| Common Equity | N/A | N/A | N/A |
| Total Shareholders Equity | $312.46M | $-225.72M | $-192.29M |
| Accumulated Minority Interest | N/A | N/A | N/A |
| Total Equity | $312.46M | $-225.72M | $-192.29M |
| Total Liabilities & Stockholders Equity | $369.97M | $68.18M | $74.58M |
| Book Value Per Share | N/A | N/A | N/A |
| Tangible Book Value Per Share | N/A | N/A | N/A |
| Full-Time Employees | N/A | N/A | N/A |
| Price to Book Ratio | N/A | N/A | N/A |
| Return on Assets | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A |
| Return on Invested Capital | N/A | N/A | N/A |
| Quick Ratio | N/A | N/A | N/A |
| Current Ratio | N/A | N/A | N/A |
| Metric | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|
| Net Income | $-156.99M | $-37.12M | $-119.28M |
| Depreciation | N/A | N/A | N/A |
| Other Funds (Non Cash) | N/A | N/A | N/A |
| Funds from Operations | N/A | N/A | N/A |
| Extraordinary Item | N/A | N/A | N/A |
| Changes in Working Capital | N/A | N/A | N/A |
| Income Taxes Payable | N/A | N/A | N/A |
| Cash from Operating Activities | $-119.67M | $-30.53M | $-65.65M |
| Capital Expenditures | N/A | N/A | N/A |
| Net Assets From Acquisitions | N/A | N/A | N/A |
| Sale of Fixed Assets and Businesses | N/A | N/A | N/A |
| Purchase or Sale of Investments | N/A | N/A | N/A |
| Purchase of Investments | N/A | N/A | N/A |
| Sale Or Maturity of Investments | N/A | N/A | N/A |
| Other Uses | N/A | N/A | N/A |
| Other Sources | N/A | N/A | N/A |
| Cash from Investing Activities | N/A | N/A | N/A |
| Cash Dividends Paid | N/A | N/A | N/A |
| Change in Capital Stock | N/A | N/A | N/A |
| Repurchase of Common Pref Stock | N/A | N/A | N/A |
| Sale of Common Pref Stock | N/A | N/A | N/A |
| Proceeds from Stock Options | N/A | N/A | N/A |
| Issuance or Reduction of Debt, Net | N/A | N/A | N/A |
| Change in Long Term Debt | N/A | N/A | N/A |
| Issuance of Long Term Debt | N/A | N/A | N/A |
| Reduction of Long Term Debt | N/A | N/A | N/A |
| Net Financing Active Other Cash Flow | N/A | N/A | N/A |
| Other Financing Activities Uses | N/A | N/A | N/A |
| Cash from Financing Activities | N/A | N/A | N/A |
| Exchange Rate Effect | N/A | N/A | N/A |
| Net Change in Cash | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A |
| Preferred Dividends (Cash Flow) | N/A | N/A | N/A |
| Price to Free Cash Flow | N/A | N/A | N/A |
Company coverage
Latest news
Zenas BioPharma Announces Data from the Registrational Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD), Simultaneously Presented at the EULAR 2026 Congress and Published in the New England Journal of MedicineGlobeNewswire Inc. Zenas BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewswire Inc. InnoCare Hits Profit Milestone, Relative Undervaluation Points To Stock UpsideBenzinga Zenas BioPharma Announces Pricing of Concurrent Public Offerings of 2.50% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $300.0 MillionGlobeNewswire Inc. ENAVATE's Zenas Bio Pharma add Is a Footnote — The Obexelimab Pipeline Is What to WatchThe Motley Fool INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Zenas BioPharma, Inc. – ZBIOGlobeNewswire Inc. INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zenas BioPharma, Inc. - ZBIOGlobeNewswire Inc. Chairman and CEO of Zenas BioPharma (ZBIO) Buys 36,928 Shares for $769,948The Motley Fool
Show 12 more stories
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zenas BioPharma, Inc. of Class Action Lawsuit and Upcoming Deadlines - ZBIOGlobeNewswire Inc. SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharmaGlobeNewswire Inc. ZBIO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Zenas BioPharma, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitGlobeNewswire Inc. Zenas BioPharma, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses; June 16, 2025 Deadline to file Lead Plaintiff MotionGlobeNewswire Inc. GoHealth, Inc. Investor News: If You Have Suffered Losses in GoHealth, Inc. (NASDAQ: GOCO), You Are Encouraged to Contact The Rosen Law Firm About Your RightsGlobeNewswire Inc. Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ibotta, NET Power, Zenas BioPharma, and Avis Budget and Encourages Investors to Contact the FirmGlobeNewswire Inc. Zenas BioPharma, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses; June 16, 2025 Deadline to file Lead Plaintiff MotionGlobeNewswire Inc. ZBIO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Zenas BioPharma, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitGlobeNewswire Inc. The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Zenas BioPharma, Inc. (ZBIO) ShareholdersGlobeNewswire Inc. Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ibotta, NET Power, Zenas BioPharma, and BigBear and Encourages Investors to Contact the FirmGlobeNewswire Inc. ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Zenas BioPharma, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – ZBIOGlobeNewswire Inc. ROSEN, THE FIRST FILING FIRM, Encourages Zenas BioPharma, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – ZBIOGlobeNewswire Inc.
Insider Trading
View AllInsider
Type
Shares
Price
Value
Date
Company
About the company
Zenas BioPharma, Inc. functions as a clinical-stage biopharmaceutical firm, concentrating on the creation and market introduction of innovative, immunology-based treatments. The company's primary investigational therapy is obexelimab, a distinctive bifunctional monoclonal antibody intended to address multiple diseases such as immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. Its developmental portfolio also features ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody. Established in 2019, the entity was formerly recognized as Zenas BioPharma (Cayman) Limited before adopting its current name, Zenas BioPharma, Inc., in August 2023. Its headquarters are located in Waltham, Massachusetts.
Discover more
You may be interested in